Dr Reddy’s launches Reddy-Lenalidomide in Canada

Dr Reddy’s Laboratories yesterday launched Reddy-Lenalidomide, a generic equivalent to Revlimid (lenalidomide) capsules in the Canadian market. The product is approved by Health Canada, the company notified in a statement.

Speaking in this regard, Vinod Ramachandran, PhD, Vice President and General Manager, Dr Reddy’s Laboratories Canada, said, “Our launch of Reddy-Lenalidomide represents our firm commitment to providing access to affordable medicines for Canada’s Multiple Myeloma and Myelodysplastic Syndrome (MDS) patient population.”

He also said, “Along with this important launch, we are pleased to introduce our Reddy2Assist Platform, which provides convenient one-stop access to assist prescribers and pharmacists with qualification requirements for patients, as well as patient onboarding and registration via web portal, telephone or fax.”

Reddy-Lenalidomide capsules are available in 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg strengths,
each in blister packs, the statement said.